Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
The U.S. spent $344 billion on prescription drugs in 2018 — 4.5% more than the year before, according to pharmaceutical data firm IQVIA.
The big picture: Society collectively paid more for drugs last year, at a rate well above economic growth, because drugmakers launched new drugs with lofty price tags, sold more of their existing drugs, and raised prices on their blockbuster products.
Between the lines: Gross spending on drugs was $479 billion in 2018, but rebates and discounts collected by health insurance companies, pharmacy benefit managers and others in the supply chain lowered that amount by 28%, thus getting to the net figure of $344 billion.
The bottom line: Pharmaceutical companies and industry middlemen benefited from higher spending in 2018, even amid the furor from patients and lawmakers over unaffordable prescriptions.
- And early federal data shows there's a chance net drug spending in 2019 may be rising at a similar rate.